These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23456389)

  • 1. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
    Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
    Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
    Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
    Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
    Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
    Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.
    Gaedcke J; Grade M; Jung K; Schirmer M; Jo P; Obermeyer C; Wolff HA; Herrmann MK; Beissbarth T; Becker H; Ried T; Ghadimi M
    Radiother Oncol; 2010 Jan; 94(1):76-81. PubMed ID: 19913317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.
    Boissière-Michot F; Lopez-Crapez E; Frugier H; Berthe ML; Ho-Pun-Cheung A; Assenat E; Maudelonde T; Lamy PJ; Bibeau F
    Mod Pathol; 2012 May; 25(5):731-9. PubMed ID: 22282307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
    Clancy C; Burke JP; Coffey JC
    Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
    Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.
    Lee JW; Lee JH; Shim BY; Kim SH; Chung MJ; Kye BH; Kim HJ; Cho HM; Jang HS
    Medicine (Baltimore); 2015 Aug; 94(31):e1284. PubMed ID: 26252300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
    Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
    Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
    BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
    Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.